<VariationArchive VariationID="417369" VariationName="NM_000527.4(LDLR):c.1846-?_2311+?del" VariationType="Deletion" Accession="VCV000417369" Version="1" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-06-23" DateCreated="2017-08-13" MostRecentSubmission="2017-08-13">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="402817" VariationID="417369">
      <GeneList>
        <Gene Symbol="LDLR" FullName="low density lipoprotein receptor" GeneID="3949" HGNC_ID="HGNC:6547" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>19p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="11089463" stop="11133820" display_start="11089463" display_stop="11133820" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="11200037" stop="11244505" display_start="11200037" display_stop="11244505" Strand="+" />
          </Location>
          <OMIM>606945</OMIM>
          <Haploinsufficiency last_evaluated="2021-10-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LDLR">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-10-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LDLR">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000527.4(LDLR):c.1846-?_2311+?del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>19p13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" innerStart="11120092" innerStop="11123344" display_start="11120092" display_stop="11123344" variantLength="3253" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" innerStart="11230768" innerStop="11234020" display_start="11230768" display_stop="11234020" variantLength="3253" />
      </Location>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_274t1" sequenceAccession="LRG_274t1" change="c.1846-?_2311+?del">
            <Expression>LRG_274t1:c.1846-?_2311+?del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.10" sequenceAccession="NC_000019" sequenceVersion="10" change="g.(?_11120092)_(11123344_?)del" Assembly="GRCh38">
            <Expression>NC_000019.10:g.(?_11120092)_(11123344_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.(?_11230768)_(11234020_?)del" Assembly="GRCh37">
            <Expression>NC_000019.9:g.(?_11230768)_(11234020_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000527.4(LDLR):c.1846-?_2311+?del AND Hypercholesterolemia, familial, 1" Accession="RCV000476635" Version="3">
        <ClassifiedConditionList TraitSetID="7435">
          <ClassifiedCondition DB="MedGen" ID="C0745103">Hypercholesterolemia, familial, 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2016-07-04" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2016-07-04" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2017-08-13" MostRecentSubmission="2017-08-13">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">21865347</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8409767</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9974426</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="7435" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15983" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hypercholesterolemia, familial, 1</ElementValue>
                <XRef ID="MONDO:0007750" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">HYPERCHOLESTEROLEMIA, FAMILIAL, MODIFIER OF</ElementValue>
                <XRef Type="Allelic variant" ID="600946.0028" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">LDL RECEPTOR DISORDER</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperlipoproteinemia Type IIa</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">HYPER-LOW-DENSITY-LIPOPROTEINEMIA</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">HYPERCHOLESTEROLEMIC XANTHOMATOSIS, FAMILIAL</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
                <XRef Type="MIM" ID="144400" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Fredrickson type IIa hyperlipoproteinemia</ElementValue>
                <XRef ID="397915002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperlipoproteinemia type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyper-beta-lipoproteinemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperlipoproteinemia Type II</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FHC</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FH</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Familial hypercholesterolemia (FH) is characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) that leads to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age and increases the risk of premature cardiovascular events such as angina and myocardial infarction; stroke occurs more rarely. Xanthomas (cholesterol deposits in tendons) may be visible in the Achilles tendons or tendons of the hands and worsen with age as a result of extremely high cholesterol levels. Xanthelasmas (yellowish, waxy deposits) can occur around the eyelids. Individuals with FH may develop corneal arcus (white, gray, or blue opaque ring in the corneal margin as a result of cholesterol deposition) at a younger age than those without FH. Individuals with a more severe phenotype, often as a result of biallelic variants, can present with very significant elevations in LDL-C (&gt;500 mg/dL), early-onset coronary artery disease (CAD; presenting as early as childhood in some), and calcific aortic valve disease.</Attribute>
                <XRef ID="NBK174884" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="NICE, 2019">
                <URL>https://www.nice.org.uk/guidance/CG71</URL>
                <CitationText>National Institute for Health and Clinical Excellence, Identification and management of familial hypercholesterolaemia, 2008 [Updated: 4 October 2019]</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="CSANZ, 2012">
                <ID Source="PubMed">22364837</ID>
              </Citation>
              <Citation Type="general" Abbrev="IPMFH, 2004">
                <ID Source="PubMed">15177124</ID>
              </Citation>
              <Citation Type="general" Abbrev="NLAEP, 2011">
                <ID Source="PubMed">21600525</ID>
              </Citation>
              <Citation Type="general" Abbrev="Int'l FH Foundation, 2014">
                <ID Source="PubMed">24418289</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24404629</ID>
                <ID Source="BookShelf">NBK174884</ID>
              </Citation>
              <Citation Type="general" Abbrev="Feldman et al., 2015">
                <ID Source="PubMed">25404096</ID>
              </Citation>
              <Citation Type="general" Abbrev="EAS, 2014">
                <ID Source="PubMed">25053660</ID>
              </Citation>
              <Citation Type="general" Abbrev="PLEF, 2014">
                <ID Source="PubMed">24636176</ID>
              </Citation>
              <Citation Type="general" Abbrev="PLEF, 2013">
                <ID Source="PubMed">23725921</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="Position Statement" Abbrev="CSANZ, 2016">
                <URL>https://www.csanz.edu.au/wp-content/uploads/2017/07/Familial-Hypercholesterolaemia_ratified_-25-Nov-2016.pdf</URL>
                <CitationText>The Cardiac Society of Australia and New Zealand, Diagnosis and Management of Familial Hypercholesterolaemia – Position Statement</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Familial-Hypercholesterolemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, APOB, LDLR, PCSK9 Pathogenic Variants (Familial Hypercholesterolemia), 2019</CitationText>
              </Citation>
              <XRef ID="391665" DB="Orphanet" />
              <XRef ID="C0745103" DB="MedGen" />
              <XRef ID="MONDO:0007750" DB="MONDO" />
              <XRef Type="MIM" ID="143890" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1076749" SubmissionDate="2017-03-14" DateLastUpdated="2017-08-13" DateCreated="2017-04-17">
        <ClinVarSubmissionID localKey="870357|MedGen:C0020445" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000563832" DateUpdated="2017-08-13" DateCreated="2017-04-17" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-07-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment Type="public">This variant is a gross deletion of the genomic region encompassing exons 13-15 of the LDLR gene. This creates a premature translational stop signal and is expected to result in an absent or disrupted protein product. Loss-of-function variants in LDLR are known to be pathogenic. Similar deletions encompassing exons 13-15 have been described in the literature in several individuals affected with hypercholesterolemia (PMID: 18718593, 15936313, 9974426, 21865347, 8409767). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="LDLR" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.(?_11230768)_(11234020_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0020445" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2017March_Invitae</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1142257" SubmissionDate="2017-08-04" DateLastUpdated="2017-08-13" DateCreated="2017-08-13">
        <ClinVarSubmissionID localKey="LDLR 1539" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000588615" DateUpdated="2017-08-13" DateCreated="2017-08-13" Type="SCV" Version="1" SubmitterName="Laboratory of Genetics and Molecular Cardiology, University of São Paulo" OrgID="505581" OrganizationCategory="laboratory" OrgAbbreviation="LGCM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-03-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <CellLine>Heterozygous patient fibroblasts; Compound heterozygous (with p.(Gly549Asp)) patients fibroblasts; Heterozygous patient Epstein-Barr virus transformed lymphocytes</CellLine>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="MethodResult">40% / 5% LDLR activity; 3 alternative splicing products: exons 13, 14 and 15 skipping (p.Asp616Leufs*17); exons 13, 14, 15 and 16 skipping (p.Asp616Cysfs*132); exons 12, 13, 14 and 15 skipping (p.Asp569_Gln770del) / 20% LDLR activity</Attribute>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <Citation>
              <ID Source="PubMed">8409767</ID>
            </Citation>
            <Citation>
              <ID Source="PubMed">9974426</ID>
            </Citation>
            <Citation>
              <ID Source="PubMed">21865347</ID>
            </Citation>
            <Comment>Assay description:Htz / Comp htz (with p.(Gly549Asp)) patients' fibroblasts, 125I-LDL and RNA assays / Htz patients' Epstein-Barr virus transformed lymphocytes, FACS assays</Comment>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="LDLR" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="19" innerStart="11230767" innerStop="11234020" outerStart="11227675" outerStop="11236352" />
          </Location>
          <OtherNameList>
            <Name>NM_000527.4:c.1846-?_2311+?del</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0020445" Type="CUI" />
          </Trait>
        </TraitSet>
        <StudyName>HipercolBrasil</StudyName>
        <StudyDescription>HipercolBrasil is a program that aims to describe the genetic data obtained from the cascade screening applied in a large FH Brazilian cohort since 2011.</StudyDescription>
        <SubmissionNameList>
          <SubmissionName>SUB2605555</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1174846" SubmissionDate="2017-04-20" DateLastUpdated="2017-08-13" DateCreated="2017-08-13">
        <ClinVarSubmissionID localKey="LDLR 1539" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000607648" DateUpdated="2017-08-13" DateCreated="2017-08-13" Type="SCV" Version="1" SubmitterName="Fundacion Hipercolesterolemia Familiar" OrgID="506180" OrganizationCategory="other" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-03-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <CellLine>heterozygous / compound heterozygous (with p.(Gly549Asp)) patients' fibroblasts</CellLine>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="MethodResult">40% / 5% LDLR activity; 3 altertive splicing products: exons 13, 14 and 15 skipping (p.Asp616Leufs*17); exons 13, 14, 15 and 16 skipping (p.Asp616Cysfs*132); exons 12, 13, 14 and 15 skipping (p.Asp569_Gln770del) / 20% LDLR activity</Attribute>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <Citation>
              <ID Source="PubMed">8409767</ID>
            </Citation>
            <Citation>
              <ID Source="PubMed">9974426</ID>
            </Citation>
            <Citation>
              <ID Source="PubMed">21865347</ID>
            </Citation>
            <Comment Type="public">Htz / Comp htz (with p.(Gly549Asp)) patients' fibroblasts, 125I-LDL and RNA assays / Htz patients' Epstein-Barr virus transformed lymphocytes, FACS assays</Comment>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="LDLR" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="19" innerStart="11230767" innerStop="11234020" outerStart="11227675" outerStop="11236352" />
          </Location>
          <OtherNameList>
            <Name>NM_000527.4:c.1846-?_2311+?del</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0020445" Type="CUI" />
          </Trait>
        </TraitSet>
        <StudyName>SAFEHEART</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB2597387</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1142257" TraitType="Disease" MappingType="XRef" MappingValue="C0020445" MappingRef="MedGen">
        <MedGen CUI="C0020445" Name="Familial hypercholesterolemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1076749" TraitType="Disease" MappingType="XRef" MappingValue="C0020445" MappingRef="MedGen">
        <MedGen CUI="C0020445" Name="Familial hypercholesterolemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1174846" TraitType="Disease" MappingType="XRef" MappingValue="C0020445" MappingRef="MedGen">
        <MedGen CUI="C0020445" Name="Familial hypercholesterolemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

